1. Home
  2. NRIX vs ODP Comparison

NRIX vs ODP Comparison

Compare NRIX & ODP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • ODP
  • Stock Information
  • Founded
  • NRIX 2009
  • ODP 1986
  • Country
  • NRIX United States
  • ODP United States
  • Employees
  • NRIX N/A
  • ODP N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • ODP Other Specialty Stores
  • Sector
  • NRIX Health Care
  • ODP Consumer Discretionary
  • Exchange
  • NRIX Nasdaq
  • ODP Nasdaq
  • Market Cap
  • NRIX 728.6M
  • ODP 611.3M
  • IPO Year
  • NRIX 2020
  • ODP N/A
  • Fundamental
  • Price
  • NRIX $8.97
  • ODP $21.82
  • Analyst Decision
  • NRIX Strong Buy
  • ODP Hold
  • Analyst Count
  • NRIX 14
  • ODP 1
  • Target Price
  • NRIX $29.07
  • ODP $19.00
  • AVG Volume (30 Days)
  • NRIX 847.4K
  • ODP 440.7K
  • Earning Date
  • NRIX 10-10-2025
  • ODP 11-05-2025
  • Dividend Yield
  • NRIX N/A
  • ODP N/A
  • EPS Growth
  • NRIX N/A
  • ODP N/A
  • EPS
  • NRIX N/A
  • ODP 0.84
  • Revenue
  • NRIX $88,381,000.00
  • ODP $6,690,000,000.00
  • Revenue This Year
  • NRIX $74.59
  • ODP N/A
  • Revenue Next Year
  • NRIX N/A
  • ODP N/A
  • P/E Ratio
  • NRIX N/A
  • ODP $26.17
  • Revenue Growth
  • NRIX 41.86
  • ODP N/A
  • 52 Week Low
  • NRIX $8.18
  • ODP $11.85
  • 52 Week High
  • NRIX $29.56
  • ODP $32.21
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 42.73
  • ODP 57.89
  • Support Level
  • NRIX $8.33
  • ODP $20.05
  • Resistance Level
  • NRIX $10.13
  • ODP $22.61
  • Average True Range (ATR)
  • NRIX 0.49
  • ODP 0.92
  • MACD
  • NRIX -0.00
  • ODP -0.01
  • Stochastic Oscillator
  • NRIX 35.56
  • ODP 74.43

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About ODP The ODP Corporation

The ODP Corp operates an integrated B2B distribution platform with divisions focusing on various sectors: ODP Business Solutions serves small to enterprise-level companies with office supplies, technology, furniture, and services. Office Depot Division caters to retail consumers and small businesses through retail locations and eCommerce platforms, offering office supplies, technology, and business services. Veyer Division specializes in supply chain, distribution, and procurement services for both internal and third-party customers, with a focus on international operations. Varis Division offers a tech-enabled B2B indirect procurement marketplace, providing a seamless buying experience and advanced spend management tools. Revenue stems from the Veyer division.

Share on Social Networks: